Naked DNA |
Extracellular space |
None |
Localized transgene expression |
Muscle(
15
,
17
), liver(
16
,
17
), spleen,
17
), kidney(
17
), brain(
18
), tumor(
19
,
20
,
21
,
22
)
|
High applicability to various targets |
Naked DNA |
Extracellular or intravascular space |
Electric pulse |
Localized transgene expression |
Muscle(
17
,
26
), liver(
17
,
27
), spleen(
17
), kidney(
17
), tumor(
25
)
|
High applicability to various targets |
Possible tissue damage caused by electric pulses |
Naked DNA |
Extracellular or intravascular space |
Ultrasound |
Localized transgene expression |
Tumor(
29
), carotid artery(
30
), femoral artery(
31
)
|
High applicability to various targets |
Naked DNA |
Intravascular space |
Massage |
Localized transgene expression |
Liver(
32
,
33
)
|
Applicability to other organs not reported |
Naked DNA |
Intravascular space |
Occlusion of blood flow |
Localized transgene expression |
Liver(
35
,
37
), diaphragm(
38
)
|
Surgery required for the occlusion |
Naked DNA |
Intravascular space |
Pre‐injection of cationic liposomes |
Lung‐selective transgene expression |
Lung endothelial cells(
36
)
|
Reduced immunostimulatory response compared with DNA–cationic liposome complexes |
Naked DNA |
Intravascular space |
Large volume injection at high speed |
Extremely high transgene expression |
Whole body(
2
,
4
,
39
)
|
Possible tissue damage |
DNA–cationic liposome complex |
Extracellular or intravascular space |
None |
Low‐level transgene expression in vivo
|
Lung endothelial cells(
46
)
|
High induction of inflammatory cytokines upon administration |
DNA–cationic polymer complex |
Extracellular or intravascular space |
None |
Low‐level transgene expression in vivo
|
Lung endothelial cells(
45
)
|
Concerns about cytotoxicity of cationic polymers |